Actualités et Activités de Gradalis
Dirigeants
Voir l'organigramme avec ses 14 principaux dirigeants
Biographies les plus recherchées chez Gradalis
- Steven Weinstein, Chief Executive Officer
- Scott Seaman, Director
- David Shanahan, Chairman of the Board
Changements de dirigeants chez Gradalis
- Steven Weinstein, a rejoint l'entreprise comme Chief Executive Officer (publié le 13 janvier 2026).
- David Shanahan qui était Chairman of the Board and Chief Executive Officer, devient Chairman of the Board (publié le 13 janvier 2026).
Créer une alerte
pour suivre les mouvements de dirigeants chez Gradalis.
Biotechnologie
Gradalis a 2 428 concurrents dont Lonza (Suisse), Vertex Pharmaceuticals (Etats—Unis) et Eurofins (Luxembourg).
Actualités en fusion/acquisition en Biotechnologie.
- Eli Lilly has announced the acquisition of AtaiBeckley (publié le 17 juillet 2026).
- GSK a acquis Nuvalent (publié le 17 juillet 2026).
- Clearside Biomedical has gone out of its bankruptcy protection (publié le 15 juillet 2026).
Contacts en Biotechnologie
Actualités
Derniers communiqués de presse par Gradalis
- Gradalis’ Vigil® Demonstrates Significant Survival Benefit in cTMB-H / HRP Ovarian Cancer Patients; Phase 2b VITAL Trial Analysis Published in JCO – Precision Oncology
- Gradalis Appoints Steven D. Weinstein as Chief Executive Officer
- Gradalis Announces Development of Clinically Relevant Exome Sequencing Bioinformatics Pipeline to Determine Clonal Tumor Mutation Burden
- Gradalis Secures FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Vigil® (Gemogenovatucel-T): An Investigational Personalized Immunotherapy for Advanced Ovarian Cancer
- Gradalis Highlights Importance of Targeting Clonal Neoantigens in Achieving Durable Benefit in Cancer Treatment
- Texas backs Carrollton firm working on ovarian cancer drug with $10 million grant
- Gradalis to Host Virtual KOL Discussion on the Vigil® Platform Entering Phase 2 for Platinum-Sensitive Recurrent Ovarian Cancer on October 25, 2023
- Gradalis Highlights Importance of Clonal Neoantigen Targeting for Clinical Benefit of Vigil® in Oncology Reviews Publication
- Gradalis Receives Clearance to Begin Pivotal Phase 3 Clinical Trial of Vigil® (gemogenovatucel-T) in Patients With Advanced Ovarian Cancer in the U.S.
- Gradalis Appoints Eric Hall as Chief Financial Officer
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Gradalis
- Gradalis sur Wikipédia, Google News & Yahoo Finance en 1-click
- Gradalis sur LinkedIn, X (Twitter) & YouTube en 1-click
